KIR2DL1/CD158a Antibody (2F9) [Alexa Fluor® 532]

Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

KIRDL2, also known as CD158a, belongs to the killer-cell immunoglobulin-like receptor (KIR) gene family expressed by natural killer (NK) cells and functions in inhibitory signaling (1,2). The KIR genes consisting of 15 gene loci and two pseudogenes are located on chromosome 19 and segregated into halptype A or B depending on gene composition (1). Human KIR2DL1 belongs to haplotype A and is synthesized as a protein of 348 amino acids (aa) in length with a theoretical molecular weight (MW) of 38.5 kDa (3). The KIR2DL1 protein consists of two extracellular immunoglobulin (Ig)-like C2 domains, a transmembrane domain, and a long cytoplasmic tail containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) (1,3). KIR2DL1 binds human leukocyte antigen (HLA) alleles with the C2 supratype, resulting in an inhibitory immune response and suppression of NK cell activity to target cells (1,2). KIR2DL1 has been shown to be a potential clinical biomarker for diseases related to suppressed NK cell function (4). An increase in inhibitory receptors such as KIR2DL1/CD158a is observed in certain pathologies like endometriosis and multiple myeloma (4,5). Therapeutic inhibition of KIR2DL1 may be a potential treatment option for endometriosis patients (5). Additionally, blocking of KIR2DL1 combined with rituximab, and anti-CD20 monoclonal antibody, has shown increased NK cell cytotoxicity than just the antibody itself (5).

References

1. Debska-Zielkowska J, Moszkowska G, Zielinski M, et al. KIR Receptors as Key Regulators of NK Cells Activity in Health and Disease. Cells. 2021;10(7):1777. Published 2021 Jul 14. https://doi.org/10.3390/cells10071777

2. Goodson-Gregg FJ, Krepel SA, Anderson SK. Tuning of human NK cells by endogenous HLA-C expression. Immunogenetics. 2020;72(4):205-215. https://doi.org/10.1007/s00251-020-01161-x

3. Uniprotkb (P43626)

4. Konjevic G, Jurisic V, Jovic V, et al. Investigation of NK cell function and their modulation in different malignancies. Immunol Res. 2012;52(1-2):139-156. https://doi.org/10.1007/s12026-012-8285-7

5. Hoogstad-van Evert J, Paap R, Nap A, van der Molen R. The Promises of Natural Killer Cell Therapy in Endometriosis. Int J Mol Sci. 2022;23(10):5539. Published 2022 May 16. https://doi.org/10.3390/ijms23105539

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NBP1-04315AF532

• KIR2DL1/CD158a Antibodies
• KIR2DL1/CD158a Proteins and Enzyme